SCHEMBL833033

SCHEMBL833033

COC(=O)[C@@H]1[C@H](C)N1C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.43
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.37
KMT2A Q03164 1/20 0.37
CES1 P23141 1/20 0.37
HTT P42858 1/20 0.36
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ATM Q13315 1/20 0.35
TSHR P16473 2/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15668595 1.00 KCNN4 (0.43) KCNN4POLBLMNAKMT2ACES1
SCHEMBL15668593 1.00 KCNN4 (0.43) KCNN4POLBLMNAKMT2ACES1
SCHEMBL6036537 1.00 KCNN4 (0.43) KCNN4POLBLMNAKMT2ACES1
SCHEMBL18649120 1.00 KCNN4 (0.43) KCNN4POLBLMNAKMT2ACES1
SCHEMBL5427678 1.00 KCNN4 (0.43) KCNN4POLBLMNAKMT2ACES1
SCHEMBL5196336 0.83 MAPT (0.37) KCNN4LMNAKMT2ACES1ALDH1A1
SCHEMBL5195703 0.83 MAPT (0.37) KCNN4LMNAKMT2ACES1ALDH1A1
SCHEMBL16498030 0.83 MAPT (0.37) KCNN4LMNAKMT2ACES1ALDH1A1
SCHEMBL3148024 0.81 HTR2C (0.46) KMT2AALDH1A1TDP1TSHRMAPK1
SCHEMBL30775651 0.81 SSTR4 (0.36) KCNN4KMT2ACES1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090509-A1 SPIRO HETEROCYCLIC CDK2 INHIBITORS ARCHITECT THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
US-20260014146-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-01-15 US disclosed
EP-4562014-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 EP disclosed
EP-4561575-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 EP disclosed
WO-2025011610-A1 AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-01-16 WO disclosed
CN-119306790-A Amide derivative, composition and use thereof 深圳市塔吉瑞生物医药有限公司 2025-01-14 CN disclosed
US-20240277795-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF PARDES BIOSCIENCES INC (US) 2024-08-22 US disclosed
US-12065445-B2 CDK2 inhibitors and methods of using the same CEDILLA THERAPEUTICS, INC. (US) 2024-08-20 US disclosed
EP-4387980-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2024-06-26 EP disclosed
US-20240174680-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-05-30 US disclosed
US-8143418-B2 Dimeric small molecule potentiators of apoptosis BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-03-27 US disclosed
US-20110124585-A1 Dimeric Small Molecule Potentiators of Apoptosis BOARD OF REGENTS 2011-05-26 US disclosed
US-7884211-B2 2-Methylamino-N-{2-(6-{1-methyl-2-(2-methylamino-propionylamino)-3-oxo-3-[2-(5-phenoxy-tetrazol-1-ylmethyl)-pyrrolidine-1-yl]-propoxy}-hexa-2,4-diynyloxy)-1-[2-(5-phenoxy-tetrazol-1-ylmethyl)-pyrrolidine-1-carbonyl]-propyl}-propionamide; mimetics of second mitochondria-derived activator of caspases BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-02-08 US disclosed
US-7816538-B2 Dimeric small molecule potentiators of apoptosis BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-10-19 US disclosed
US-7638544-B2 Dimeric small molecule potentiators of apoptosis BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-12-29 US disclosed
US-20090312379-A1 Dimeric Small Molecule Potentiators of Apoptosis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-12-17 US disclosed
US-20090281155-A1 Dimeric Small Molecule Potentiators of Apoptosis BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2009-11-12 US disclosed
US-20080119532-A1 Dimeric Small Molecule Potentiators of Apoptosis BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2008-05-22 US disclosed
US-7309792-B2 Dimeric small molecule potentiators of apoptosis BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2007-12-18 US disclosed
US-20050197403-A1 Dimeric small molecule potentiators of apoptosis BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312379-A1 Dimeric Small Molecule Potentiators of Apoptosis BAD, BAX, CASP2 KCNN4 4747/4885POLB 983/4885LMNA 85/4885
US-20090281155-A1 Dimeric Small Molecule Potentiators of Apoptosis BAD, BAX, CASP2 KCNN4 4747/4885POLB 983/4885LMNA 85/4885
US-20240174680-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK20, CDK2AP2 KCNN4 4772/4885POLB 144/4885LMNA 792/4885
US-20110124585-A1 Dimeric Small Molecule Potentiators of Apoptosis BAD, BAX, CASP2 KCNN4 4747/4885POLB 983/4885LMNA 85/4885
US-20080119532-A1 Dimeric Small Molecule Potentiators of Apoptosis BAD, BAX, CASP2 KCNN4 4730/4885POLB 1035/4885LMNA 93/4885
US-20240277795-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CPN1, CTSL KCNN4 4745/4885POLB 2783/4885LMNA 2949/4885
US-20050197403-A1 Dimeric small molecule potentiators of apoptosis BAD, BAX, CASP2 KCNN4 4734/4885POLB 959/4885LMNA 94/4885
US-12065445-B2 CDK2 inhibitors and methods of using the same CDK2, CDK20, CDK1 KCNN4 4649/4885POLB 216/4885LMNA 971/4885
US-20260014146-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK20, CDK1 KCNN4 3757/4885POLB 126/4885LMNA 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.